Jose Cangiano, MD
Psychiatry · Athens, GANPI 1487755724
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $192,354 of the $244,141 with a category attached, or 78.8%. Johnson & Johnson accounts for 73.6% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $91,583 and has fallen 70.3% since, to $27,209 in 2025. Among psychiatry clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 352 payments — averaging $693.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$180K
- E.r. Squibb & Sons, L.L.C.$64K
- Otsuka America Pharmaceutical, Inc.$110
- Lundbeck LLC$103
- Alkermes, Inc.$79
- Teva Pharmaceuticals USA, Inc.$63
- plus $108 from 4 others
Across 1 payment — averaging $241.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$242
What the payments were for
- Consulting fees$13,3405%
- Speaking & faculty fees$192,35479%
- Travel & lodging$31,57713%
- Food & beverage$6,8713%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 250 | $179,674 |
| E.r. Squibb & Sons, L.L.C. | 74 | $64,003 |
| Otsuka America Pharmaceutical, Inc. | 6 | $110 |
| Lundbeck LLC | 6 | $103 |
| Alkermes, Inc. | 5 | $79 |
| Teva Pharmaceuticals USA, Inc. | 5 | $63 |
| Neurocrine Biosciences, Inc. | 3 | $53 |
| AbbVie | 1 | $24 |
| Indivior Inc. | 1 | $19 |
| Vanda Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$176,389
- INVEGA TRINZA$169,185
- COBENFY$39,243
How this compares
$244,141 in reported general payments places this provider in the 95th percentile of 900 psychiatry providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 27 | $244,508 |
| Invega SustennaPaliperidone Palmitate | 56 | $169,802 |
| Invega TrinzaPaliperidone Palmitate | 16 | $113,493 |
| AustedoDeutetrabenazine | 19 | $92,973 |
| Wellbutrin XlBupropion Hcl | 14 | $76,646 |
| AristadaAripiprazole Lauroxil | 24 | $76,157 |
| Abilify MaintenaAripiprazole | 23 | $66,156 |
| Aripiprazole | 153 | $25,741 |
| AuvelityDextromethorphan Hbr/Bupropion | 13 | $12,849 |
| Clozapine | 164 | $10,340 |
| Olanzapine | 157 | $8,959 |
| Seroquel XrQuetiapine Fumarate | 12 | $8,733 |
| SeroquelQuetiapine Fumarate | 13 | $7,606 |
| Paliperidone ErPaliperidone | 20 | $6,241 |
| Quetiapine Fumarate | 213 | $5,430 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna, Invega Trinza | $179,674 | $283,29472 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $53 | $244,50827 claims |
| Teva Pharmaceuticals USA, Inc.Austedo | $63 | $92,97319 claims |
| Alkermes, Inc.Aristada | $79 | $76,15724 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena | $110 | $66,15623 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 900 psychiatry providers in Georgia.
Other psychiatry in Athens
- Richard PettyLoganville$2.9M
- Ann GrooverCalhoun$1.4M
- Todd AntinDecatur$1M
- Michael BanovMarietta$733K
- Ben HunterBrookhaven$499K
- Joel MorganValdosta$337K
- Munjal ShroffSmyrna$316K
- David PurselleAtlanta$307K
- Michael BurkeAtlanta$217K
- Bryon EvansAtlanta$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.